Effects of sodium‐glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients
An erratum to this article was published (Diabetes Obes Metab, Jun 2023 ↗)
Authors' conclusion
Combination therapy with SGLT2-Is and MRAs was associated with lower albuminuria in patients with type 2 DM compared with monotherapy with SGLT2-Is or MRAs alone.
Study context
- Population
- Patients with T2D and urinary albumin-creatinine ratio (UACR) ≥30 mg/g creatinine; databases searched from inception to 20 November 2022
- Participants
- 34,412 patients17 studies
- Comparison
- SGLT2-Is + mineralocorticoid receptor antagonists (MRAs) vs SGLT2-Is, MRAs or placebo
- Outcome
- Change in UACR
Methodological detailsrandomized control and crossover trials, sensitivity analyses
- Randomized control and crossover trials
- Sensitivity analyses
Pooled result
As reported in the abstract
Mean difference
- SGLT2-Is + MRAs vs SGLT2-Is
- −34.19 (95% CI −27.30 to −41.08)
- SGLT2-Is + MRAs vs MRAs
- −32.25 (95% CI −24.53 to −39.97)
- SGLT2-Is + MRAs vs Placebo
- −65.22 (95% CI −57.97 to −72.47)
- SGLT2-Is vs Placebo
- −31.03 (95% CI −28.35 to −33.72)
- MRAs vs Placebo
- −32.97 (95% CI −29.68 to −36.27)
Further pooled results
- Sensitivity analyses showed similar results
Original publication
Effects of sodium‐glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients. Diabetes Obes Metab. Published 2 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →